245 related articles for article (PubMed ID: 29433938)
1. B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.
Zhao X; Zhang Z; Moreira D; Su YL; Won H; Adamus T; Dong Z; Liang Y; Yin HH; Swiderski P; Pillai RK; Kwak L; Forman S; Kortylewski M
Mol Ther; 2018 Mar; 26(3):695-707. PubMed ID: 29433938
[TBL] [Abstract][Full Text] [Related]
2. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.
Zhang Q; Hossain DM; Duttagupta P; Moreira D; Zhao X; Won H; Buettner R; Nechaev S; Majka M; Zhang B; Cai Q; Swiderski P; Kuo YH; Forman S; Marcucci G; Kortylewski M
Blood; 2016 Mar; 127(13):1687-700. PubMed ID: 26796361
[TBL] [Abstract][Full Text] [Related]
3. Targeted In Vivo Delivery of NF-κB Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy.
Zhang Z; Zhao X; Wang D; Moreira D; Su YL; Alcantara M; Swiderski P; Wong J; Hui S; Forman S; Kwak L; Kortylewski M
Mol Ther; 2021 Mar; 29(3):1214-1225. PubMed ID: 33248246
[TBL] [Abstract][Full Text] [Related]
4. STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers.
Moreira D; Adamus T; Zhao X; Su YL; Zhang Z; White SV; Swiderski P; Lu X; DePinho RA; Pal SK; Kortylewski M
Clin Cancer Res; 2018 Dec; 24(23):5948-5962. PubMed ID: 30337279
[TBL] [Abstract][Full Text] [Related]
5. Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.
Kortylewski M; Moreira D
Cancer Immunol Immunother; 2017 Aug; 66(8):979-988. PubMed ID: 28214929
[TBL] [Abstract][Full Text] [Related]
6. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.
Hossain DM; Dos Santos C; Zhang Q; Kozlowska A; Liu H; Gao C; Moreira D; Swiderski P; Jozwiak A; Kline J; Forman S; Bhatia R; Kuo YH; Kortylewski M
Blood; 2014 Jan; 123(1):15-25. PubMed ID: 24169824
[TBL] [Abstract][Full Text] [Related]
7. β-Adrenergic Signaling Impairs Antitumor CD8
Nissen MD; Sloan EK; Mattarollo SR
Cancer Immunol Res; 2018 Jan; 6(1):98-109. PubMed ID: 29146881
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
9. The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma.
Pradhan P; Qin H; Leleux JA; Gwak D; Sakamaki I; Kwak LW; Roy K
Biomaterials; 2014 Jul; 35(21):5491-504. PubMed ID: 24720881
[TBL] [Abstract][Full Text] [Related]
10. Intracellular osteopontin protects from autoimmunity-driven lymphoma development inhibiting TLR9-MYD88-STAT3 signaling.
Rizzello C; Cancila V; Sangaletti S; Botti L; Ratti C; Milani M; Dugo M; Bertoni F; Tripodo C; Chiodoni C; Colombo MP
Mol Cancer; 2022 Dec; 21(1):215. PubMed ID: 36503430
[TBL] [Abstract][Full Text] [Related]
11. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.
Zhang Q; Hossain DM; Nechaev S; Kozlowska A; Zhang W; Liu Y; Kowolik CM; Swiderski P; Rossi JJ; Forman S; Pal S; Bhatia R; Raubitschek A; Yu H; Kortylewski M
Blood; 2013 Feb; 121(8):1304-15. PubMed ID: 23287859
[TBL] [Abstract][Full Text] [Related]
12. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.
Won H; Moreira D; Gao C; Duttagupta P; Zhao X; Manuel E; Diamond D; Yuan YC; Liu Z; Jones J; D'Apuzzo M; Pal S; Kortylewski M
J Leukoc Biol; 2017 Aug; 102(2):423-436. PubMed ID: 28533357
[TBL] [Abstract][Full Text] [Related]
13. Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma.
Zhou B; Yan J; Guo L; Zhang B; Liu S; Yu M; Chen Z; Zhang K; Zhang W; Li X; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Li H; Ye Q
Theranostics; 2020; 10(14):6530-6543. PubMed ID: 32483468
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer-induced immune suppression in the sentinel lymph node is effectively countered by CpG-B in conjunction with inhibition of the JAK2/STAT3 pathway.
van Pul KM; Vuylsteke RJCLM; de Beijer MTA; van de Ven R; van den Tol MP; Stockmann HBAC; de Gruijl TD
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33046620
[TBL] [Abstract][Full Text] [Related]
15. CpG oligodeoxynucleotide induces apoptosis and cell cycle arrest in A20 lymphoma cells via TLR9-mediated pathways.
Qi XF; Zheng L; Kim CS; Lee KJ; Kim DH; Cai DQ; Qin JW; Yu YH; Wu Z; Kim SK
Mol Immunol; 2013 Jul; 54(3-4):327-37. PubMed ID: 23357786
[TBL] [Abstract][Full Text] [Related]
16. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself.
Li J; Song W; Czerwinski DK; Varghese B; Uematsu S; Akira S; Krieg AM; Levy R
J Immunol; 2007 Aug; 179(4):2493-500. PubMed ID: 17675511
[TBL] [Abstract][Full Text] [Related]
17. Role of Toll-like receptor 9 signaling on activation of nasal polyp-derived fibroblasts and its association with nasal polypogenesis.
Park SK; Jin SY; Yeon SH; Lee SB; Xu J; Yoon YH; Rha KS; Kim YM
Int Forum Allergy Rhinol; 2018 Sep; 8(9):1001-1012. PubMed ID: 29901280
[TBL] [Abstract][Full Text] [Related]
18. TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells.
Moreira D; Zhang Q; Hossain DM; Nechaev S; Li H; Kowolik CM; D'Apuzzo M; Forman S; Jones J; Pal SK; Kortylewski M
Oncotarget; 2015 Jul; 6(19):17302-13. PubMed ID: 26046794
[TBL] [Abstract][Full Text] [Related]
19. Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy.
Alcantara MB; Tang WS; Wang D; Kaniowski D; Kang E; Dizman N; Chehrazi-Raffle A; Meza L; Zengin Z; Hall J; Hsu J; Egelston C; Moreira D; Horsager A; Pal SK; Kortylewski M
Front Immunol; 2023; 14():1274781. PubMed ID: 38259453
[TBL] [Abstract][Full Text] [Related]
20. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma.
Scuto A; Kujawski M; Kowolik C; Krymskaya L; Wang L; Weiss LM; Digiusto D; Yu H; Forman S; Jove R
Cancer Res; 2011 May; 71(9):3182-8. PubMed ID: 21521803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
